Supplier log in
Future Procurement Opportunity (FPO) – Supply of permanent coronary drug eluting stents under a market share arrangement
Details
|
Tender Closed
|
|
| RFx ID : | 25197649 |
| Tender Name : | Future Procurement Opportunity (FPO) – Supply of permanent coronary drug eluting stents under a market share arrangement |
| Reference # : | A1546689 |
| Open Date : | Q4 2021 |
| Indicative RFx Release Date : | Q1 2022 [?] |
| Tender Type : | Future Procurement Opportunity (FPO) |
| Project Status : | Confirmed [?] |
| Indicative Total Value : | $10M - $25M [?] |
| Expected number of contracts offered : | 1 |
| Categories : |
|
| Regions: |
|
| Required Pre-qualifications : | None |
| Contact : |
Pharmac Procurement Team procurement@pharmac.govt.nz |
| Related Tenders: | |
Pharmac is planning on issuing a competitive process for supply of permanent coronary drug eluting stents under a market share arrangement. Pharmac currently has a market share arrangement in place for permanent coronary drug eluting stents for a single supplier with a 65% minimum market share.
The approximate gross annual expenditure of all permanent coronary drug eluting stents in the 2020/21 FYR was $6,572,000. Under the current market share DHB hospitals are expected to use the successful supplier for a minimum of 65% of their usage.
Further detail and notification of approval of the current market share arrangement is available here: https://pharmac.govt.nz/hospital-devices/whats-happening-in-each-category/permanent-coronary-drug-eluting-stents/.
Pharmac would hold a supplier briefing in relation to this procurement process once the RFP has been released. Further information would be available on the Pharmac website for suppliers to pre-register.
